Andere talen Atea Pharmaceuticals, Inc.

Aandelen

AVIR

US04683R1068

Geschatte realtime Cboe BZX Andere beurzen 15:35:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,79 ^USD	+2,43%		-0,80%	+21,31%

27/03	Atea Pharmaceuticals, Inc. Voltooit de patiëntenregistratie in de wereldwijde Fase 3 Sunrise-3-studie waarin het orale antivirale Bemnifosbuvir voor COVID-19 bij hoogrisicopatiënten wordt geëvalueerd	CI
28/02	Atea Pharmaceuticals, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024	29/04
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	27/03
Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	27/03
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	28/02
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024	21/02
Atea Pharmaceuticals Reports 'Positive' Results on Hepatitis C Virus, COVID Trials; Shares Jump After Hours	08/01
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19	08/01
Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19	08/01
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Atea Pharmaceuticals Says Bemnifosbuvir, Ruzasvir Combination Results Show Promise to Treat Hepatitis C Virus	13/11
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023	13/11
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	08/11
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences	08/11
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023	02/11
Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023	02/11
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023	01/11
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	06-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Atea Pharmaceuticals, Inc.

Aandelen

AVIR

US04683R1068

Andere talen

Filters